Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

The genomics of heart failure: design and rationale of the HERMES consortium

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{19258eb8d43143ceb163f9cd18d9ff1f,
title = "The genomics of heart failure: design and rationale of the HERMES consortium",
abstract = "AIMS: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure.METHODS AND RESULTS: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34-90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01-0.05) at P < 5 × 10-8 under an additive genetic model.CONCLUSIONS: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.",
keywords = "Association studies, Biomarkers, Cardiomyopathy, Genetics, Heart failure",
author = "Lumbers, {R Thomas} and Sonia Shah and Honghuang Lin and Tomasz Czuba and Albert Henry and Swerdlow, {Daniel I} and Anders M{\"a}larstig and Charlotte Andersson and Niek Verweij and Holmes, {Michael V} and Johan {\"A}rnl{\"o}v and Per Svensson and Harry Hemingway and Neneh Sallah and Peter Almgren and Aragam, {Krishna G} and Geraldine Asselin and Backman, {Joshua D} and Biggs, {Mary L} and Bloom, {Heather L} and Eric Boersma and Jeffrey Brandimarto and Brown, {Michael R} and {Brunner-La Rocca}, Hans-Peter and Carey, {David J} and Chaffin, {Mark D} and Chasman, {Daniel I} and Olympe Chazara and Xing Chen and Xu Chen and Chung, {Jonathan H} and William Chutkow and Cleland, {John G F} and Cook, {James P} and {de Denus}, Simon and Abbas Dehghan and Delgado, {Graciela E} and Spiros Denaxas and Doney, {Alexander S} and Marcus D{\"o}rr and Dudley, {Samuel C} and Gunnar Engstr{\"o}m and T{\~o}nu Esko and Ghazaleh Fatemifar and Felix, {Stephan B} and Chris Finan and Lars K{\o}ber and Steen Stender and Christian Torp-Pedersen and Weeke, {Peter E} and {Regeneron Genetics Center}",
note = "{\textcopyright} 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.",
year = "2021",
month = sep,
day = "3",
doi = "10.1002/ehf2.13517",
language = "English",
journal = "E S C Heart Failure",
issn = "2055-5822",
publisher = "JohnWiley & Sons Ltd",

}

RIS

TY - JOUR

T1 - The genomics of heart failure

T2 - design and rationale of the HERMES consortium

AU - Lumbers, R Thomas

AU - Shah, Sonia

AU - Lin, Honghuang

AU - Czuba, Tomasz

AU - Henry, Albert

AU - Swerdlow, Daniel I

AU - Mälarstig, Anders

AU - Andersson, Charlotte

AU - Verweij, Niek

AU - Holmes, Michael V

AU - Ärnlöv, Johan

AU - Svensson, Per

AU - Hemingway, Harry

AU - Sallah, Neneh

AU - Almgren, Peter

AU - Aragam, Krishna G

AU - Asselin, Geraldine

AU - Backman, Joshua D

AU - Biggs, Mary L

AU - Bloom, Heather L

AU - Boersma, Eric

AU - Brandimarto, Jeffrey

AU - Brown, Michael R

AU - Brunner-La Rocca, Hans-Peter

AU - Carey, David J

AU - Chaffin, Mark D

AU - Chasman, Daniel I

AU - Chazara, Olympe

AU - Chen, Xing

AU - Chen, Xu

AU - Chung, Jonathan H

AU - Chutkow, William

AU - Cleland, John G F

AU - Cook, James P

AU - de Denus, Simon

AU - Dehghan, Abbas

AU - Delgado, Graciela E

AU - Denaxas, Spiros

AU - Doney, Alexander S

AU - Dörr, Marcus

AU - Dudley, Samuel C

AU - Engström, Gunnar

AU - Esko, Tõnu

AU - Fatemifar, Ghazaleh

AU - Felix, Stephan B

AU - Finan, Chris

AU - Køber, Lars

AU - Stender, Steen

AU - Torp-Pedersen, Christian

AU - Weeke, Peter E

AU - Regeneron Genetics Center

N1 - © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

PY - 2021/9/3

Y1 - 2021/9/3

N2 - AIMS: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure.METHODS AND RESULTS: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34-90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01-0.05) at P < 5 × 10-8 under an additive genetic model.CONCLUSIONS: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.

AB - AIMS: The HERMES (HEart failure Molecular Epidemiology for Therapeutic targetS) consortium aims to identify the genomic and molecular basis of heart failure.METHODS AND RESULTS: The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34-90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of ≥1.10 for common variants (allele frequency ≥ 0.05) and ≥1.20 for low-frequency variants (allele frequency 0.01-0.05) at P < 5 × 10-8 under an additive genetic model.CONCLUSIONS: HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.

KW - Association studies

KW - Biomarkers

KW - Cardiomyopathy

KW - Genetics

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=85114632006&partnerID=8YFLogxK

U2 - 10.1002/ehf2.13517

DO - 10.1002/ehf2.13517

M3 - Journal article

C2 - 34480422

JO - E S C Heart Failure

JF - E S C Heart Failure

SN - 2055-5822

ER -

ID: 67645399